01—Abstract
Summary
Summary of the 10-K filed March 30, 2001. Cited figures are marked; the original filing is the authoritative source.
Neurocrine Biosciences, Inc. reported a net loss of $28.8 milliona, or $1.30 per share, for the year ended December 31, 2000, compared with a net loss of $16.8 million, or $0.88 per share, in 1999.
Total revenues were $14.6 millionb, down from $16.8 million in 1999, mainly because the Novartis collaboration ended in January 2000 and the sponsored research portion of the Eli Lilly collaboration ended in October 1999. Research and development expenses rose to $40.2 million from $29.2 million, and the company says it expects operating losses to increase as clinical development expands. The balance sheet strengthened over the year.
Cash, cash equivalents and short-term investments totaled $164.7 millionc at year-end, up from $91.1 million, driven mainly by a December 2000 public offering of 3.2 million shares at $30 per share that produced net proceeds of $90.4 million. Stockholders' equity was $163.2 million, and the accumulated deficit reached $70.5 million. The company states that its existing capital resources, together with interest income and future alliance payments, will be sufficient for at least the next 12 months.
The company's lead programs are NBI-34060, a GABA-A agonist for insomnia now in Phase II, and an IL-4 fusion toxin for malignant glioma. In 2001, it expects to spend about $35 milliond on clinical testing of the brain cancer and insomnia compounds.
In December 2000, Taisho's collaboration on NBI-6024 for Type 1 diabetes was expanded to worldwide rights, with the collaboration valued at up to $100 million. The filing also notes that the 2000 net loss includes a $3.8 million cumulative effect from the adoption of SAB 101 on license fee revenue recognition.
02—Key points
Key Highlights
- Net loss widened to $28.8 million ($1.30 per share) in 2000 from $16.8 million ($0.88 per share) in 1999.
- Total revenues fell to $14.6 million from $16.8 million, reflecting the end of the Novartis agreement and the Eli Lilly sponsored research portion.
- Research and development expense increased to $40.2 million from $29.2 million as drug candidates advanced through clinical phases.
- Cash, cash equivalents and short-term investments reached $164.7 million at December 31, 2000, following a December 2000 public offering with net proceeds of $90.4 million.
- Net cash used in operating activities was $18.6 million in 2000, compared with $10.3 million in 1999.
- The Taisho collaboration for NBI-6024 (Type 1 diabetes) was expanded to worldwide rights and is valued at up to $100 million.
- NBI-34060 for insomnia is in Phase II, and the company expects to spend about $35 million in 2001 on clinical testing of the insomnia and brain cancer compounds.
03—Questions
Frequently Asked Questions
Why did Neurocrine's revenues decline in 2000?
The filing attributes the decline from $16.8 million in 1999 to $14.6 million in 2000 primarily to the conclusion of the Novartis collaboration in January 2000 and the sponsored research portion of the Eli Lilly collaboration in October 1999. Revenue from Taisho of $7.1 million partly offset these losses.
How is Neurocrine funded, and how long will its cash last?
The company funded operations primarily through public and private stock offerings and payments under research agreements. Cash, cash equivalents and short-term investments were $164.7 million at year-end 2000. Management believes these resources, along with interest income and future alliance payments, will be sufficient for at least the next 12 months, but it cannot guarantee that they will cover the planned programs, and it says it will likely need additional funding.
What are the company's most advanced product candidates?
The lead candidate is NBI-34060, a GABA-A agonist for insomnia, which is in Phase II. The IL-4 fusion toxin NBI-3001 for malignant glioma is also in Phase II. Other programs include NBI-6024, an altered peptide ligand for Type 1 diabetes in Phase I/II with Taisho, and NBI-5788 for multiple sclerosis in Phase II.
What does the SAB 101 adoption mean for 2000 results?
The company adopted SAB 101 on revenue recognition in the fourth quarter of 2000. It determined that $4.2 million of 2000 license fees were subject to the change and deferred them. The cumulative effect increased the reported net loss for 2000 by approximately $3.8 million, and the deferred fees will be recognized as income at $915,000 in 2001 and smaller amounts through 2005.
What are the risks investors should consider?
The filing highlights that the company has incurred a cumulative deficit of $70.5 million and expects operating losses to grow as clinical programs advance. It notes that development can be halted at any time, that clinical trials and regulatory approvals are uncertain, and that additional financing may not be available on acceptable terms. Some of its programs also depend on collaborators, and the company cannot estimate the time or resources Wyeth-Ayerst will commit to its excitatory amino acid transporters program.
04—Continue